Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 33, 2015, Pages 10443-10448

  Sung, Pil Soo ^a   Cheon, HyeonJoo ^b   Cho, Chung Hwan ^a   Hong, Seon Hui ^a   Park, Do Youn ^c   Seo, Hyung Il ^c   Park, Su Hyung ^a   Yoon, Seung Kew ^d   Stark, George R ^b   Shin, Eui Cheol ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Pusan National University School of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Hepatitis C virus; Interferon; Interferon stimulated genes; U ISGF3

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DEUBIQUITINASE; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 15; INTERFERON STIMULATED GENE FACTOR 3; LAMBDA INTERFERON; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR 3; UBIQUITIN SPECIFIC PROTEASE 18; UNCLASSIFIED DRUG; INTERFERON; IRF9 PROTEIN, HUMAN; PROTEINASE; STAT1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN; TYROSINE; USP18 PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CHRONIC HEPATITIS C; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INNATE IMMUNITY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN UNPHOSPHORYLATION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; VIRUS ACTIVATION; VIRUS REPLICATION; CELL LINE; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; HEP-G2 CELL LINE; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; LENTIVIRINAE; LIVER; METABOLISM; PHOSPHORYLATION; VIROLOGY;

HEPATITIS C VIRUS;

CELL LINE; ENDOPEPTIDASES; HEK293 CELLS; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; INTERFERONS; LENTIVIRUS; LIVER; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TYROSINE;

EID: 84939823954     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1513341112     Document Type: Article

References (37)

1. Jeong SW, Jang JY, Chung RT (2012) Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol 18(4):347-356.
2. Horner SM, Gale M, Jr (2013) Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19(7):879-888.
3. Marukian S, et al. (2011) Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology 54(6):1913-1923.
4. Park H, et al. (2012) IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56(6):2060-2070.
5. Thomas E, et al. (2012) HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142(4):978-988.
6. Israelow B, Narbus CM, Sourisseau M, Evans MJ (2014) HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 60(4):1170-1179.
7. Wieland S, et al. (2014) Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59(6):2121-2130.
8. Park SH, Rehermann B (2014) Immune responses to HCV and other hepatitis viruses. Immunity 40(1):13-24.
9. Su AI, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99(24):15669-15674.
10. Wieland SF, Chisari FV (2005) Stealth and cunning: Hepatitis B and hepatitis C viruses. J Virol 79(15):9369-9380.
11. Dill MT, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3):1021-1031.
12. Sarasin-Filipowicz M, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105(19):7034-7039.
13. Chen L, et al. (2010) Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138(3):1123-33.e1-3.
14. Feld JJ, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46(5):1548-1563.
15. Honda M, et al.; Hokuriku Liver Study Group (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2):499-509.
16. Broering R, et al. (2010) The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 59(8): 1111-1119.
17. Francois-Newton V, Livingstone M, Payelle-Brogard B, Uzé G, Pellegrini S (2012) USP18 establishes the transcriptional and anti-proliferative interferon α/β differential. Biochem J 446(3):509-516.
18. Darnell JE, Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421.
19. Stark GR, Darnell JE, Jr (2012) The JAK-STAT pathway at twenty. Immunity 36(4):503-514.
20. Doyle SE, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896-906.
21. Bolen CR, Ding S, Robek MD, Kleinstein SH (2014) Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59(4):1262-1272.
22. Jilg N, et al. (2014) Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59(4):1250-1261.
23. Cheon H, Borden EC, Stark GR (2014) Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol 41(2):156-173.
24. Cheon H, et al. (2013) IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 32(20):2751-2763.
25. Cheon H, Stark GR (2009) Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 106(23):9373-9378.
26. Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR (2000) How Stat1 mediates constitutive gene expression: A complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J 19(15):4111-4122.
27. Zhang X, et al. (2015) Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature 517(7532):89-93.
28. Dill MT, et al. (2014) Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 124(4):1568-1581.
29. McKendry R, et al. (1991) High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc Natl Acad Sci USA 88(24):11455-11459.
30. Malakhova OA, et al. (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 17(4):455-460.
31. Randall G, et al. (2006) Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131(5):1584-1591.
32. Sarasin-Filipowicz M, et al. (2009) Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29(17):4841-4851.
33. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH (2011) Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology 53(4):1154-1163.
34. Gripon P, et al. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99(24):15655-15660.
35. Kang W, Shin EC (2012) Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions. PLoS One 7(8):e43960.
36. Steenbergen RH, et al. (2013) Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology 58(6):1907-1917.
37. Sung PS, et al. (2014) Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells. J Virol 88(16):9233-9244.